Skip to main content

Table 1 Overview of studies with sirolimus

From: Practical considerations for the use of mTOR inhibitors

Author Study arm Control arm Outcome
Ekberg et al. [1] Dac + SRL low + MMF + S (a) CsA + MMF + S (d) Higher AR in SRL arm (a. 37 %, b 24 %, c 12 %, d 26 %)
Dac + CsA low + MMF + S (b)
Dac + Tac low + MMF + S (c)
Flechner et al. [6] Dac + SRL + MMF + S (e) Dac + Tac + MMF + S (g) Higher AR in SRL/MMF (e 31 %, f 15 %, g 8 %)
Dac + SRL + Tac WD + S (f)
Flechner et al. [7] Dac + SRL + MMF + S Dac + CsA + MMF + S Better GFR in SRL arm (67 vs. 51 mL/min)
Lebranchu et al. [8] Thy + SRL + MMF + S Thy + CsA + MMF + S Better GFR in SRL arm (54 vs. 45 mL/min)
Lebranchu et al. [9] Dac + CsA + MMF + S early conversion to SRL Dac + CsA + MMF + S Better GFR in SRL arm (69 vs. 64 mL/min)
c [12] CNI + MMF+/−S (+/− induction) early conversion to SRL CNI + MMF+/−S (+/− induction) No difference in GFR change at 2 yrs
Guba et al. [15] ATG + CsA + MMF + S very early conversion ATG + CsA + MMF + S Better GFR in SRL arm (65 vs. 53 mL/min)
  1. Dac Daclizumab, SRL Sirolimus, MMF Mycophenolate mofetil, S steroids, CsA Cyclosporine A, Tac Tacrolimus, AR acute rejection rate, WD withdrawal, GFR glomerular filtration rate, Thy Thymoglobuline®, CNI Calcineurin inhibitor, ATG ATG Fresenius®